Target validation Efficacy in animals Assay development Phase I clinical trial Screening and hits to leads Phase II clinical trial Lead optimization None Safety and toxicity in animals Other Please specify: 5. Research will have a significant impact in which neurodegenerative disease(s) of aging? (Select only those that apply. There is no benefit to selecting more diseases than fewer diseases.) Alzheimer’s disease Vascular contributions to the listed diseases Dementia with Lewy bodies (not stroke-mediated vascular disease) Frontotemporal dementia Prodromes to the listed diseases (please also Multiple system atrophy check the disease(s) to which your condition is Parkinson’s disease a prodrome) Progressive supranuclear palsy 6. Relevance of proposed work to the Institute’s mandate: using the Institute’s definitions (please refer to Institute definitions), explain how the primary tool or therapeutic being developed in this project (as identified in question 2 above) is translational research, and will accelerate the development of therapeutics for neurodegenerative diseases of aging. For tools, this requires addressing how the tool will have direct impact on accelerating translational research on therapeutics. (maximum 200 words.) 7. What type of tool(s) and/or therapeutic(s) is being developed aside from the primary goal of the project as indicated above? (E.g., do not select “Animal model” unless you are developing a new animal model. There is no benefit to selecting more items than fewer items.) Tool Therapeutic Complementary approaches Animal model Biologic Sleep intervention Assay/screen Cell therapy Exercise intervention Biomarker Electrical brain stimulation Diet intervention Cell line Magnetic brain stimulation Nutritional supplement Clinical assessment instruments Medical device Diagnostic Small molecule Imaging technique or reagent Surgical intervention New method of drug delivery Vaccine Probe Other Please specify: Other Please specify: None If you selected ‘biomarker’ above, what is the primary purpose of the biomarker? Diagnostic – determine whether patients have a particular disease or disease subset Prognostic – indicate future clinical progression
Target validation Assay development Screening and hits to leads Lead optimization Safety and toxicity in animals Efficacy in animals Phase I clinical trial Phase II clinical trial None Other Please specify: 5. Research will have a significant impact in which neurodegenerative disease(s) of aging? (Select only those that apply. There is no benefit to selecting more diseases than fewer diseases.) Alzheimer’s disease Dementia with Lewy bodies Frontotemporal dementia Multiple system atrophy Parkinson’s disease Progressive supranuclear palsy Vascular contributions to the listed diseases (not stroke-mediated vascular disease) Prodromes to the listed diseases (please also check the disease(s) to which your condition is a prodrome) 6. Relevance of proposed work to the Institute’s mandate: using the Institute’s definitions (please refer to Institute definitions), explain how the primary tool or therapeutic being developed in this project (as identified in question 2 above) is translational research, and will accelerate the development of therapeutics for neurodegenerative diseases of aging. For tools, this requires addressing how the tool will have direct impact on accelerating translational research on therapeutics. (maximum 200 words.) 7. What type of tool(s) and/or therapeutic(s) is being developed aside from the primary goal of the project as indicated above? (E.g., do not select “Animal model” unless you are developing a new animal model. There is no benefit to selecting more items than fewer items.) Tool Animal model Assay/screen Biomarker Cell line Clinical assessment instruments Diagnostic Imaging technique or reagent New method of drug delivery Probe Other Please specify: Therapeutic Biologic Cell therapy Electrical brain stimulation Magnetic brain stimulation Medical device Small molecule Surgical intervention Vaccine Other Please specify: None Complementary approaches Sleep intervention Exercise intervention Diet intervention Nutritional supplement If you selected ‘biomarker’ above, what is the primary purpose of the biomarker? Diagnostic – determine whether patients have a particular disease or disease subset Prognostic – indicate future clinical progression